Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

PFE 31.94 -0.03 (-0.09%)
price chart
Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced an agreement with Pfizer for ...
Verastem Enters Agreement With Pfizer For Worldwide Commercial Right For VS ...  RTT News
Verastem Inks Separate Deals for Wnt and FAK Inhibitors  Genetic Engineering News
Related articles »  
Is Pfizer A Good Buy?
Pfizer has been involved in a series of acquisitions and sell offs, some cheered and some criticized by investors. They recently sold off their nutrition business to Nestle for $11.9 billion.
Pfizer Needs Big Earnings Beat
Pfizer Defends $25 Fair Value With Lyrica Patent Lawsuit Win  Trefis
Related articles »  
For Pfizer, Boston's medical labs a lure
Pfizer Inc., the world's largest pharmaceutical company, has a storied history of hunting for blockbuster drugs in its own labs.
Related articles »  
Why We Think Pfizer Remains Significantly Undervalued
If a company is undervalued both on a DCF and on a relative valuation basis and is showing improvement in technical and momentum indicators, it scores high on our scale.
Related articles »  
Pfizer Stock Worth $25 Despite Lawsuits And Lipitor Patent Expiry
Pfizer (NYSE:PFE) has seen its stock underperform some of its peers like Abbott Labs (NYSE:ABT) and Merck (NYSE:MRK), as the company continues to struggle with various lawsuits and complaints. Last week, five large retailers sued the company accusing ...
Related articles »  
Pfizer Announces Topline Results Of First Of Four Studies In Bapineuzumab ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC ...
Pfizer-J&J Alzheimer's Drug Fails to Aid Cognition  Bloomberg
Alzheimer's Drug Fails Its First Big Clinical Trial  New York Times
Related articles »  
Alnylam Pushes Forward In Amyloidosis After Pfizer Setback
Considering lack of progress in the RNAi space to date and the fact that the drug, ALN-TTR02, is one the company's biggest pipeline hopes, this makes encouraging news, particularly as a phase II study has already started.
Alnylam Gains on Treatment Data for Deadly Nerve Disease  Bloomberg
Positive results from Alnylam's ALN-TTR02 Phase I trial on TTR-mediated ...
Related articles »  
Pfizer Led Corporate America's Biggest Givers Last Year
Pfizer Inc. (PFE:US), the world's largest drugmaker, was corporate America's largest donor for a third straight year, granting $3.1 billion in gifts in 2011.
Related articles »  
Pharmacies Sue Pfizer Over Lipitor
Five retailers joined a legal battle against Pfizer Inc., accusing the drug maker of using anticompetitive tactics to delay the introduction of competing generic copies of Pfizer's blockbuster cholesterol-lowering pill Lipitor.
Walgreens, Kroger Sue Pfizer For Delay Of Generic Lipitor  Law360 (subscription)
Pfizer sued by retailers for generic Lipitor delay  Fox News
Related articles »  
Pfizer 2Q net income rises 25 pct on lower costs
A Jan. 25, 2009 file photo, shows Pfizer's world headquarters in New York. Pfizer Inc. reported Tuesday July 31, 2012, its second-quarter net income jumped 25 percent as sharply lower production, marketing and restructuring costs more than �more.
Pfizer IPO, Cost Cuts Yield Time to Reinvent Its Research  Bloomberg
Pfizer's Cost-Cuts Offset Loss of Lipitor  Wall Street Journal
Related articles »